Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Magnesium Chloride Anhydrous SCHEMBL29084761 | 0.92 | CYP11B1 (0.32) | CYP11B1CYP11B2MEN1CYP2C19KMT2A | |
| SCHEMBL533185 | 0.91 | MEN1 (0.37) | CYP11B1CYP11B2MEN1CYP2C19KMT2A | |
| SCHEMBL9451018 | 0.83 | MEN1 (0.41) | CYP11B1CYP11B2MEN1CYP2C19KMT2A | |
| SCHEMBL28647280 | 0.83 | MEN1 (0.32) | MEN1CYP2C19KMT2A | |
| SCHEMBL472727 | 0.81 | MEN1 (0.37) | MEN1CYP2C19KMT2A | |
| SCHEMBL2879085 | 0.77 | MEN1 (0.34) | MEN1CYP2C19KMT2A | |
| SCHEMBL27614062 | 0.77 | CYP2C19 (0.35) | CYP11B1CYP11B2MEN1CYP2C19KMT2A | |
| SCHEMBL733501 | 0.76 | CYP2C19 (0.58) | MEN1CYP2C19KMT2ASMN1; SMN2 | |
| SCHEMBL533266 | 0.76 | KCNH2 (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL533376 | 0.74 | KCNH2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0463488-B2 | O-Benzyl oxime ethers and fungicides containing them | BASF AG (DE) | 2004-04-21 | — | — | EP | claimed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
| EP-0463488-B2 | O-Benzyl oxime ethers and fungicides containing them | BASF AG (DE) | 2004-04-21 | — | — | EP | disclosed |
| CN-1466572-A | Pyrrole derivatives | ס����ҩ��ʽ���� | 2004-01-07 | — | — | CN | disclosed |
| US-RE37839-E1 | O-benzyloxime ethers and crop protection agents containing these compounds | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-10 | — | — | US | disclosed |
| US-6326399-B1 | CONTROLLING INSECTS, ARACHNIDS, NEMATODES | BASF AKTIENGESELLSCHAFT (DE) | 2001-12-04 | — | — | US | disclosed |
| US-6316459-B1 | O-benzyloxime ethers and crop protection agents containing these compounds | BASF AG (DE) | 2001-11-13 | — | — | US | disclosed |
| US-6211190-B1 | Pyrimidine derivatives, process and intermediate products for their preparation and pesticides or fungicides containing these derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | CYP11B1 518/4885CYP11B2 228/4885MEN1 4120/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | CYP11B1 541/4885CYP11B2 264/4885MEN1 4385/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | CYP11B1 32/4885CYP11B2 25/4885MEN1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.